ArticleACS omega2025
Optimization and Validation of the UPLC Method for Rapid, Facile, and Simultaneous Analysis of Sitagliptin and Metformin in Quality Control Samples.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many clinical trials have shown the effectiveness of combination therapy over monotherapy in diabetes management. Sitagliptin (SG) and metformin (MF) are the most common combinations for type II diabetes management. These drugs were combined into one tablet, called Janumet 50/850 (SG/MF). The pharmaceutical industry constantly demands a rapid, simple, sensitive, and valid analytical method for simultaneously determining drugs in pharmaceutical products. Therefore, this study aims to develop an ultraperformance liquid chromatography method for concurrently estimating metformin and sitagliptin in a short run time by applying the response surface methodology. A Box-Behnken design was implemented to study the influence of three independent factors: aqueous phase concentration in the mobile phase (A; 5-15%), mobile phase flow rate (B; 0.4-1 mL/min), and ammonium formate buffer strength (C; 5-20 mM). The data analysis showed a significant negative effect of the flow rate on the retention time and peak area. The optimized analytical condition was performed with 15% aqueous phase concentration, a flow rate of 0.52 mL/min, and a buffer strength of five mM. The analytical method was valid per the International Conference of Harmonization (ICH) guidelines. SG and MF were separated in a short time run of 2 min. The process was reliable in separating and extracting the drugs from the marketed Janumet tablets at a retention time of 0.73 and 1.36 min for SG and MF, respectively.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.